AVEO News and Press, AVEO Pharmaceuticals Inc. From 03/14/22

Gainers: Volt Information Sciences (NYSE:VOLT) +96%. Red Cat Holdings (OTCQB:RCAT) +46%. Turquoise Hill Resources (NYSE:TRQ) +32%. Zhongchao (NASDAQ:ZCMD) +29%. Mullen Automotive (NASDAQ:MULN) +28%. AgriFORCE Growing Systems (NASDAQ:AGRI) +26%. FirstMark Horizon Acquisition (NYSE:FMAC) +23%. ...

AVEO Pharmaceuticals press release (NASDAQ:AVEO): Q4 GAAP EPS of -$0.21 beats by $0.07. Revenue of $17.65M (+1883.1% Y/Y) misses by $0.7M. AVEO believes that its $87.3 million in cash, cash equivalents and marketable securities as of December 31, 2021, along with expected net produc...

– Total 2021 Net Revenue of $42.3 Million – – FOTIVDA ® (tivozanib) U.S. Net Product Revenue of $38.9 Million since March 22, 2021 – – FOTIVDA U.S. Net Product Revenue of $16.8 Million for 4Q 2021, Driven by a 26% I...

ADAP, AVEO, BLDP, CORR, GOL, JAGX, LUNA, MTBC, PEI, PRTK For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open

It appears as if AVEO Oncology is off to a strong start. The company is expected to report their fourth-quarter and full-year 2021 earnings on March 14th. I have stayed cautiously optimistic about AVEO’s performance in anticipation the Street will continue to be skeptical about...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report full year 2021 financial results on Monday, March 14, 2022. AVEO’s management team will host a conference ...

Actinium Pharmaceuticals, Inc. and AVEO Oncology Enter Research Collaboration Agreement to Develop First-in-Class Actinium-225 ErbB3 Targeting Radiotherapy for Solid Tumors - Actinium to apply its proprietary Antibody Warhead Enabling (AWE) technology platform to perform conjuga...

Five year follow-up data show FOTIVDA ® (tivozanib) patients up to 5X more likely to experience long-term PFS compared to Nexavar ® (sorafenib) Long-term data from pivotal TIVO-3 study continue to demonstrate durable disease control and positive trend for overa...

BOSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in a fireside chat at the 11 th Annual SVB Leerink Global Healthcare C...